Several VEGF plus TKI plus immune checkpoint inhibitor combinations have shown efficacy in those previously treated with immune checkpoint inhibitors in other tumor types such as renal cell carcinoma, and these could be potentially adapted to HCC [87]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.